# Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

> **NCT03927170** · PHASE1 · COMPLETED · sponsor: **GL Pharm Tech Corporation** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **COMBINATION_PRODUCT:** Janumet XR tablet 100/1000 mg
- **COMBINATION_PRODUCT:** GLH1SM tablet 100/1000 mg

## Key facts

- **NCT ID:** NCT03927170
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-10-23
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927170, "Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03927170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*